Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention

Donnelly, Richard; Manning, Gillian

doi:10.3317/jraas.2007.002

Cited by 15 publications

(9 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many studies demonstrating a significant improvement in both survival and quality of life with ACEIs and/or ARBs among patients with heart failure. 6 However, appropriate selection of patients for treatment with ACEIs and/or ARBs is challenging. Currently many patients without heart failure are using these medications.…”

Section: Discussionmentioning

confidence: 99%

CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers

Darabian

Luo

Homat

et al. 2015

Coronary Artery Disease

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers

Darabian

Luo

Homat

et al. 2015

Coronary Artery Disease

View full text Add to dashboard Cite

“…Ang II also provokes a wide range of tissue responses, most of which are mediated via AT1R, by promoting apoptosis, inflammation, and fibrosis. [12][13][14] Therefore, ACE inhibitors and Ang II receptor blockers (ARBs), targeting Ang II directly or indirectly, have been widely used to treat hypertension, ventricular remodeling, or coronary heart disease 15,16 and are currently the first-line treatment of hypertension, especially when complicated with diabetes mellitus or renal failure.…”

mentioning

confidence: 99%

Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of Hypertension

et al. 2016

View full text Add to dashboard Cite

Abstract-Dipeptidyl peptidase III (DPP III) cleaves dipeptide residues from the N terminus of polypeptides ranging from 3 to 10 amino acids in length and is implicated in pathophysiological processes through the breakdown of certain oligopeptides or their fragments. In this study, we newly identified the biochemical properties of DPP III for angiotensin II (Ang II), which consists of 8 amino acids. DPP III quickly and effectively digested Ang II with K m = 3.7×10 −6 mol/L. In the in vivo experiments, DPP III remarkably reduced blood pressure in Ang II-infused hypertensive mice without alteration of heart rate. DPP III did not affect hemodynamics in noradrenalin-induced hypertensive mice or normotensive mice, suggesting specificity for Ang II. When DPP III was intravenously injected every other day for 4 weeks after Ang II osmotic minipump implantation in mice, Ang II-induced cardiac fibrosis and hypertrophy were significantly attenuated. This DPP III effect was at least similar to that caused by an angiotensin receptor blocker candesartan. Furthermore, administration of DPP III dramatically reduced the increase in urine albumin excretion and kidney injury and inflammation markers caused by Ang II infusion. Both DPP III and candesartan administration showed slight additive inhibition in the albumin excretion. These results reveal a novel potential use of DPP III in the treatment of hypertension and its protective effects on hypertension-sensitive organs, such as the heart and kidneys.

show abstract

“…For example, angiotensin-converting enzyme (ACE) inhibitors have been proposed to reduce cardiovascular disease events beyond what would be predicted based on their blood pressure lowering alone [98]. Basic animal model research using mice in which the angiotensin II receptor type 1a has been deleted has demonstrated profound protection from atherosclerosis [99,100].…”

Section: Medications With Pleiotropic Actionsmentioning

confidence: 99%

Advances in the management of hyperlipidemia-induced atherosclerosis

Tannock¹

2008

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Although hyperlipidemia clearly plays a role in developing cardiovascular disease, the 10% of the population with the highest LDL levels account for only 20% of cardiovascular disease events. Thus, in order to significantly reduce the burden of cardiovascular disease, subjects with only modest dyslipidemia need to be treated with lipid-lowering therapy. Current guidelines have recommended aggressive lipid-lowering therapy in subjects at high risk of cardiovascular disease. The rationale behind this and treatment options to achieve target lipid goals are discussed.

show abstract

Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention

Cited by 15 publications

References 51 publications

CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers

CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers

Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of Hypertension

Advances in the management of hyperlipidemia-induced atherosclerosis

Contact Info

Product

Resources

About